GILD Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
My Notes
Capture your thoughts, links and company narrative
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$104.08 |
| 52 Week High | US$106.69 |
| 52 Week Low | US$62.07 |
| Beta | 0.20 |
| 1 Month Change | 13.33% |
| 3 Month Change | 17.66% |
| 1 Year Change | 45.40% |
| 3 Year Change | 70.48% |
| 5 Year Change | 49.33% |
| Change since IPO | 16,347.22% |
Recent News & Updates
Recent updates
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Feb 11Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt
Feb 09
Gilead: Strong Sales Growth Remains With Veklury And Beyond
Feb 03Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise
Dec 29Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
Dec 18Gilead Sciences, Inc.'s (NASDAQ:GILD) Business And Shares Still Trailing The Industry
Dec 13We Think You Can Look Beyond Gilead Sciences' (NASDAQ:GILD) Lackluster Earnings
Nov 13Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Nov 07Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It
Oct 01Gilead Sciences: Buy This Bargain Before It's Gone
Aug 30Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?
Aug 05A Look At Gilead Sciences After Its Recent Weakness
Jul 27Gilead Records Positive Phase III Results In HIV
Jun 22Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?
Jun 13Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
May 23We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation
May 02Shareholder Returns
| GILD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.4% | 0.4% | 1.5% |
| 1Y | 45.4% | -2.7% | 22.4% |
Return vs Industry: GILD exceeded the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: GILD exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| GILD volatility | |
|---|---|
| GILD Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GILD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GILD's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 18,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| GILD fundamental statistics | |
|---|---|
| Market cap | US$129.71b |
| Earnings (TTM) | US$480.00m |
| Revenue (TTM) | US$28.75b |
270.2x
P/E Ratio4.5x
P/S RatioIs GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GILD income statement (TTM) | |
|---|---|
| Revenue | US$28.75b |
| Cost of Revenue | US$6.25b |
| Gross Profit | US$22.50b |
| Other Expenses | US$22.02b |
| Earnings | US$480.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 24, 2025
| Earnings per share (EPS) | 0.39 |
| Gross Margin | 78.26% |
| Net Profit Margin | 1.67% |
| Debt/Equity Ratio | 144.2% |
How did GILD perform over the long term?
See historical performance and comparisonDividends
3.0%
Current Dividend Yield800%
Payout RatioDoes GILD pay a reliable dividends?
See GILD dividend history and benchmarks| Gilead Sciences dividend dates | |
|---|---|
| Ex Dividend Date | Mar 14 2025 |
| Dividend Pay Date | Mar 28 2025 |
| Days until Ex dividend | 26 days |
| Days until Dividend pay date | 40 days |
Does GILD pay a reliable dividends?
See GILD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 02:52 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gilead Sciences, Inc. is covered by 69 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |